Two Major Drugs Pushed Back In One Day - The Return Of A Stricter US FDA?
COVID Vaccines and Alzheimer's Drug Will Be Next Tests
Executive Summary
Knock-backs for Gilead/Galapagos and BioMarin are a surprise, and could be a sign of the FDA reasserting its 'gold standard' approach to safety and efficacy.